These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 2036621)

  • 1. MPTP-induced neurotoxicity and the quest for a preventative therapy for Parkinson's disease.
    Furtado JC; Mazurek MF
    Can J Neurol Sci; 1991 Feb; 18(1):77-82. PubMed ID: 2036621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Parkinsonism induced by MPTP as an experimental model of Parkinson disease: similarities and differences].
    Luquin MR; Obeso JA; Herrero MT; Laguna J; Martínez-Lage JM
    Neurologia; 1991 Oct; 6(8):287-94. PubMed ID: 1790005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [MPTP: a new chapter in the history of Parkinson's disease].
    Piccinin GL; Piccirilli M; Finali G; Stefano E
    Riv Neurol; 1989; 59(3):103-7. PubMed ID: 2688042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MPTP-induced parkinsonism as a model for Parkinson's disease.
    Tetrud JW; Langston JW
    Acta Neurol Scand Suppl; 1989; 126():35-40. PubMed ID: 2694734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level.
    Kupsch A; Sautter J; Schwarz J; Riederer P; Gerlach M; Oertel WH
    Brain Res; 1996 Nov; 741(1-2):185-96. PubMed ID: 9001722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unexpected toxicity of very low dose MPTP in mice: A clue to the etiology of Parkinson's disease?
    Dovero S; Gross C; Bezard E
    Synapse; 2016 Feb; 70(2):49-51. PubMed ID: 26583879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Significance of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine for the etiology and therapy of idiopathic Parkinson disease].
    Lange KW
    Fortschr Neurol Psychiatr; 1989 Apr; 57(4):142-8. PubMed ID: 2656447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The MPTP-lesioned non-human primate models of Parkinson's disease. Past, present, and future.
    Fox SH; Brotchie JM
    Prog Brain Res; 2010; 184():133-57. PubMed ID: 20887873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metallobiology of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity.
    Hare DJ; Adlard PA; Doble PA; Finkelstein DI
    Metallomics; 2013 Feb; 5(2):91-109. PubMed ID: 23322189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Environmental MPTP as a factor in the aetiology of Parkinson's disease?
    Goodwin BL; Kite GC
    J Neural Transm (Vienna); 1998; 105(10-12):1265-9. PubMed ID: 9928895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nongenetic causes of Parkinson's disease.
    Chade AR; Kasten M; Tanner CM
    J Neural Transm Suppl; 2006; (70):147-51. PubMed ID: 17017522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of MPTP toxicity.
    Przedborski S; Jackson-Lewis V
    Mov Disord; 1998; 13 Suppl 1():35-8. PubMed ID: 9613716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Might environmental factors contribute to neurodegenerative diseases?
    Tipton KF
    Biochem Soc Trans; 1995 May; 23(2):429-35. PubMed ID: 7672436
    [No Abstract]   [Full Text] [Related]  

  • 14. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
    Jenner P; Marsden CD
    J Neural Transm Suppl; 1986; 20():11-39. PubMed ID: 3091760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Midbrain dopaminergic cell loss in Parkinson's disease and MPTP-induced parkinsonism: sparing of calbindin-D28k-containing cells.
    German DC; Manaye KF; Sonsalla PK; Brooks BA
    Ann N Y Acad Sci; 1992 May; 648():42-62. PubMed ID: 1353337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): implications for treatment and the pathogenesis of Parkinson's disease.
    Langston JW; Ballard P
    Can J Neurol Sci; 1984 Feb; 11(1 Suppl):160-5. PubMed ID: 6608979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
    Burns RS; LeWitt PA; Ebert MH; Pakkenberg H; Kopin IJ
    N Engl J Med; 1985 May; 312(22):1418-21. PubMed ID: 2581135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MPTP and other Parkinson-inducing agents.
    Schapira AH
    Curr Opin Neurol Neurosurg; 1992 Jun; 5(3):396-400. PubMed ID: 1623269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Similarity and dissimilarity of MPTP models to Parkinson's disease: importance of juvenile parkinsonism.
    Narabayashi H
    Eur Neurol; 1987; 26 Suppl 1():24-9. PubMed ID: 3495438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The MPTP model of Parkinson's disease.
    Smeyne RJ; Jackson-Lewis V
    Brain Res Mol Brain Res; 2005 Mar; 134(1):57-66. PubMed ID: 15790530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.